Literature DB >> 29688881

Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma.

Jennifer A Locke1, Reza Hamidizadeh1, Wassim Kassouf2, Ricardo A Rendon3, David Bell3, Jonathan Izawa4, Joseph Chin4, Anil Kapoor5, Bobby Shayegen5, Jean-Baptiste Lattouf6, Fred Saad6, Louis Lacombe7, Yves Fradet7, Adrien S Fairey8, Niels-Eric Jacobson8, Darrel E Drachenberg9, Ilias Cagiannos10, Alan I So1, Peter C Black1.   

Abstract

INTRODUCTION: Upper tract urothelial carcinoma (UTUC) accounts for 5% of all urothelial tumours. Due to its rarity, evidence regarding postoperative surveillance is lacking. The objective of this study was to develop a post-radical nephroureterectomy (RNU) surveillance protocol based on recurrence patterns in a large, multi-institutional cohort of patients.
METHODS: Retrospective clinical and pathological data were collected from 1029 patients undergoing RNU over a 15-year period (1994-2009) at 10 Canadian academic institutions. A multivariable model was used to identify prognostic clinicopathological factors, which were then used to define risk categories. Risk-based surveillance guidelines were proposed based on actual recurrence patterns.
RESULTS: Overall, 555 (49.9%) patients developed recurrence, including 289 (25.9%) in the urothelium and 266 (23.9%) with loco-regional and distant recurrences. Based on multivariable analysis, three risk groups were identified: 1) low-risk patients with pTa-T1, pN0 disease, and no adverse histological features (high tumour grade, lymphovascular invasion [LVI], tumour multifocality); 2) intermediate-risk patients with pTa-T1, pN0 disease with one or more of the adverse histological features; and 3) high-risk patients with a ≥pT2 tumour and/or nodal involvement. Low-, intermediate-, and high-risk patients were free of urothelial recurrence at three years in 72%, 66%, and 63%, respectively, and free of regional/distant recurrence in 93%, 87%, and 62%, respectively. The risks of loco-regional and distant recurrences (p<0.0001) and time to death (p<0.0001) were significantly different between the low-, intermediate-, and high-risk patients.
CONCLUSIONS: Based on recurrence patterns in a large, multicentre patient cohort, we have proposed an evidence-based, risk-adapted post-RNU surveillance protocol.

Entities:  

Year:  2018        PMID: 29688881      PMCID: PMC6114151          DOI: 10.5489/cuaj.5377

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  24 in total

1.  Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.

Authors:  Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

2.  [European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract].

Authors:  M Rouprêt; R Zigeuner; J Palou; A Boehle; E Kaasinen; R Sylvester; M Babjuk; W Oosterlinck
Journal:  Actas Urol Esp       Date:  2011-10-29       Impact factor: 0.994

3.  Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery.

Authors:  Michael Rink; Behfar Ehdaie; Eugene K Cha; David A Green; Pierre I Karakiewicz; Marko Babjuk; Vitaly Margulis; Jay D Raman; Robert S Svatek; Harun Fajkovic; Richard K Lee; Giacomo Novara; Jens Hansen; Siamak Daneshmand; Yair Lotan; Wassim Kassouf; Hans-Martin Fritsche; Armin Pycha; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2012-02-15       Impact factor: 20.096

4.  Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients.

Authors:  Wolfgang Otto; Shahrokh F Shariat; Hans-Martin Fritsche; Amit Gupta; Kazumasa Matsumoto; Wassim Kassouf; Guido Martignoni; Thomas J Walton; Stefan Tritschler; Shiro Baba; Patrick J Bastian; Juan I Martínez-Salamanca; Christian Seitz; Armin Pycha; Maximilian Burger; Pierre I Karakiewicz; Vincenzo Ficarra; Giacomo Novara
Journal:  World J Urol       Date:  2011-01-20       Impact factor: 4.226

5.  Oncological followup after radical cystectomy for bladder cancer-is there any benefit?

Authors:  Bjoern G Volkmer; Rainer Kuefer; Georg C Bartsch; Kilian Gust; Richard E Hautmann
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

Review 6.  Staging and reporting of urothelial carcinoma of the urinary bladder.

Authors:  Liang Cheng; Rodolfo Montironi; Darrell D Davidson; Antonio Lopez-Beltran
Journal:  Mod Pathol       Date:  2009-06       Impact factor: 7.842

7.  Survival impact of followup care after radical cystectomy for bladder cancer.

Authors:  Seth A Strope; Su-Hsin Chang; Ling Chen; Gurdarshan Sandhu; Jay F Piccirillo; Mario Schootman
Journal:  J Urol       Date:  2013-05-29       Impact factor: 7.450

Review 8.  The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement?

Authors:  Jonathan I Epstein
Journal:  Crit Rev Oncol Hematol       Date:  2003-08       Impact factor: 6.312

9.  Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool.

Authors:  Evanguelos Xylinas; Luis Kluth; Niccolo Passoni; Quoc-Dien Trinh; Malte Rieken; Richard K Lee; Harun Fajkovic; Giacomo Novara; Vitaly Margulis; Jay D Raman; Yair Lotan; Morgan Rouprêt; Atiqullah Aziz; Hans-Martin Fritsche; Alon Weizer; Juan I Martinez-Salamanca; Kazumasa Matsumoto; Christian Seitz; Mesut Remzi; Thomas Walton; Pierre I Karakiewicz; Francesco Montorsi; Marc Zerbib; Douglas S Scherr; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2013-09-19       Impact factor: 20.096

10.  Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram.

Authors:  D R Yates; V Hupertan; P Colin; A Ouzzane; A Descazeaud; J A Long; G Pignot; S Crouzet; F Rozet; Y Neuzillet; M Soulie; T Bodin; A Valeri; O Cussenot; M Rouprêt
Journal:  Br J Cancer       Date:  2012-02-28       Impact factor: 7.640

View more
  3 in total

1.  Association Between Anesthetic Technique and Survival After Radical Nephroureterectomy: A Propensity Score-matching Study.

Authors:  Yudai Ishiyama; Tsunenori Kondo; Hidekazu Tachibana; Hiroki Ishihara; Haruka Ito Nishioki; Kazuhiko Yoshida; Junpei Iizuka; Kazunari Tanabe; Toshio Takagi
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.

Authors:  Yu-Chan Kang; Ming-Hong Chen; Chung-Ying Lin; Chih-Yun Lin; Yen-Ta Chen
Journal:  Ther Adv Drug Saf       Date:  2021-03-21

3.  Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors.

Authors:  Jean-Michel Lavoie; Gillian Vandekerkhove; Andrew J Murtha; Gang Wang; Alexander W Wyatt; Bernhard J Eigl
Journal:  Urol Case Rep       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.